Literature DB >> 19104016

Population pharmacokinetics of emtricitabine in human immunodeficiency virus type 1-infected pregnant women and their neonates.

Déborah Hirt1, Saik Urien, Elisabeth Rey, Elise Arrivé, Didier K Ekouévi, Patrick Coffié, Sim Kruy Leang, Sarita Lalsab, Divine Avit, Eric Nerrienet, James McIntyre, Stéphane Blanche, François Dabis, Jean-Marc Tréluyer.   

Abstract

The objectives of this study were to evaluate emtricitabine (FTC) pharmacokinetics in pregnant women and their neonates and to determine the optimal prophylactic dose for neonates after birth to prevent mother-to-child transmission of human immunodeficiency virus (HIV). A total of 38 HIV-infected pregnant women were administered tenofovir disoproxyl fumarate (300 mg)-FTC (200 mg) tablets-two tablets at the initiation of labor and one daily for 7 days postpartum. By pair, 11 maternal, one cord blood, and two neonatal FTC concentrations were measured using a high-performance liquid chromatography-tandem mass spectrometry validated method and analyzed by a population approach. Model and mean estimates (interpatient variability) were a two-compartment model for mothers, with an absorption rate constant of 0.54 h(-1) (61%), apparent elimination and intercompartmental clearances of 23.2 (17%) and 6.04 liters x h(-1), and apparent central and peripheral volumes of 127 and 237 liters, respectively; an effect compartment linked to maternal circulation for cord blood and a neonatal compartment disconnected, after delivery, with a 10.6-h half-life (30%). After the 400-mg FTC administration, the median population area under the concentration-time curve and the minimal and maximal plasma FTC concentrations in pregnant women were 14.3 mg x liter(-1) x h and 1.68 and 0.076 mg/liter, respectively. At delivery, median (range) predicted maternal and cord blood FTC concentrations were, respectively, 1.16 (0.14 to 1.99) and 0.72 (0.05 to 1.19) mg x liter(-1). We concluded that the 400-mg FTC administration in pregnant women produces higher exposition than does the 200-mg administration in other adults, at steady state. FTC was shown to have good placental transfer (80%). Administering 1 mg FTC/kg as soon as possible after birth or 2 mg/kg 12 h after birth should produce neonatal concentrations comparable to the concentrations observed in adults.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19104016      PMCID: PMC2650537          DOI: 10.1128/AAC.00860-08

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  14 in total

1.  Ways to fit a PK model with some data below the quantification limit.

Authors:  S L Beal
Journal:  J Pharmacokinet Pharmacodyn       Date:  2001-10       Impact factor: 2.745

Review 2.  Pharmacokinetic changes during pregnancy and their clinical relevance.

Authors:  R Loebstein; A Lalkin; G Koren
Journal:  Clin Pharmacokinet       Date:  1997-11       Impact factor: 6.447

3.  Transit time in the small intestine in pregnancy.

Authors:  E Parry; R Shields; A C Turnbull
Journal:  J Obstet Gynaecol Br Commonw       Date:  1970-10

4.  Antiretroviral pharmacology in pregnant women and their newborns.

Authors:  M Mirochnick
Journal:  Ann N Y Acad Sci       Date:  2000-11       Impact factor: 5.691

5.  Systemic pharmacokinetics and cellular pharmacology of zidovudine in human immunodeficiency virus type 1-infected women and newborn infants.

Authors:  J H Rodman; P M Flynn; B Robbins; E Jimenez; A D Bardeguez; J F Rodriguez; S Blanchard; A Fridland
Journal:  J Infect Dis       Date:  1999-12       Impact factor: 5.226

6.  Identification of the K103N resistance mutation in Ugandan women receiving nevirapine to prevent HIV-1 vertical transmission.

Authors:  J B Jackson; G Becker-Pergola; L A Guay; P Musoke; M Mracna; M G Fowler; L M Mofenson; M Mirochnick; F Mmiro; S H Eshleman
Journal:  AIDS       Date:  2000-07-28       Impact factor: 4.177

7.  Nevirapine (NVP) resistance in women with HIV-1 subtype C, compared with subtypes A and D, after the administration of single-dose NVP.

Authors:  Susan H Eshleman; Donald R Hoover; Shu Chen; Sarah E Hudelson; Laura A Guay; Anthony Mwatha; Susan A Fiscus; Francis Mmiro; Philippa Musoke; J Brooks Jackson; Newton Kumwenda; Taha Taha
Journal:  J Infect Dis       Date:  2005-06-01       Impact factor: 5.226

8.  Steady-state pharmacokinetics of emtricitabine and tenofovir disoproxil fumarate administered alone and in combination in healthy volunteers.

Authors:  M Robert Blum; Gregory E Chittick; John A Begley; Jian Zong
Journal:  J Clin Pharmacol       Date:  2007-06       Impact factor: 3.126

9.  Pharmacokinetics and safety of single oral doses of emtricitabine in human immunodeficiency virus-infected children.

Authors:  Laurene H Wang; Andrew A Wiznia; Mobeen H Rathore; Gregory E Chittick; Saroj S Bakshi; Patricia J Emmanuel; Patricia M Flynn
Journal:  Antimicrob Agents Chemother       Date:  2004-01       Impact factor: 5.191

10.  Quantification of seven nucleoside/nucleotide reverse transcriptase inhibitors in human plasma by high-performance liquid chromatography with tandem mass-spectrometry.

Authors:  Thomas Le Saux; Stéphanie Chhun; Elisabeth Rey; Odile Launay; Laurence Weiss; Jean-Paul Viard; Gérard Pons; Vincent Jullien
Journal:  J Chromatogr B Analyt Technol Biomed Life Sci       Date:  2008-03-05       Impact factor: 3.205

View more
  22 in total

1.  Effect of pregnancy on emtricitabine pharmacokinetics.

Authors:  A M Stek; B M Best; W Luo; E Capparelli; S Burchett; C Hu; H Li; J S Read; A Jennings; E Barr; E Smith; S S Rossi; M Mirochnick
Journal:  HIV Med       Date:  2011-11-30       Impact factor: 3.180

Review 2.  Toward a universal antiretroviral regimen: special considerations of pregnancy and breast feeding.

Authors:  Amy L Slogrove; Polly Clayden; Elaine J Abrams
Journal:  Curr Opin HIV AIDS       Date:  2017-07       Impact factor: 4.283

3.  Prediction of human fetal pharmacokinetics using ex vivo human placenta perfusion studies and physiologically based models.

Authors:  Maïlys De Sousa Mendes; Deborah Hirt; Cécile Vinot; Elodie Valade; Gabrielle Lui; Claire Pressiat; Naïm Bouazza; Frantz Foissac; Stephane Blanche; Minh Patrick Lê; Gilles Peytavin; Jean-Marc Treluyer; Saik Urien; Sihem Benaboud
Journal:  Br J Clin Pharmacol       Date:  2016-01-12       Impact factor: 4.335

Review 4.  Pharmacokinetic studies in infants using minimal-risk study designs.

Authors:  Julie Autmizguine; Daniel K Benjamin; P Brian Smith; Mario Sampson; Philippe Ovetchkine; Michael Cohen-Wolkowiez; Kevin M Watt
Journal:  Curr Clin Pharmacol       Date:  2014

5.  Modified renal function in pregnancy: impact on emtricitabine pharmacokinetics.

Authors:  Elodie Valade; Jean-Marc Tréluyer; François Dabis; Elise Arrivé; Emmanuelle Pannier; Sihem Benaboud; Floris Fauchet; Naïm Bouazza; Frantz Foissac; Saïk Urien; Déborah Hirt
Journal:  Br J Clin Pharmacol       Date:  2014-12       Impact factor: 4.335

6.  Concentrations of tenofovir and emtricitabine in breast milk of HIV-1-infected women in Abidjan, Cote d'Ivoire, in the ANRS 12109 TEmAA Study, Step 2.

Authors:  Sihem Benaboud; Alain Pruvost; Patrick A Coffie; Didier K Ekouévi; Saïk Urien; Elise Arrivé; Stéphane Blanche; Frédéric Théodoro; Divine Avit; François Dabis; Jean-Marc Tréluyer; Déborah Hirt
Journal:  Antimicrob Agents Chemother       Date:  2010-12-20       Impact factor: 5.191

7.  Multiple Drug Transporters Contribute to the Placental Transfer of Emtricitabine.

Authors:  Qingquan Zeng; Mengru Bai; Cui Li; Shuanghui Lu; Zhiyuan Ma; Yunchun Zhao; Hui Zhou; Huidi Jiang; Dongli Sun; Caihong Zheng
Journal:  Antimicrob Agents Chemother       Date:  2019-07-25       Impact factor: 5.191

8.  A Physiologically-Based Pharmacokinetic Model to Predict Human Fetal Exposure for a Drug Metabolized by Several CYP450 Pathways.

Authors:  Maïlys De Sousa Mendes; Gabrielle Lui; Yi Zheng; Claire Pressiat; Deborah Hirt; Elodie Valade; Naïm Bouazza; Frantz Foissac; Stephane Blanche; Jean-Marc Treluyer; Saik Urien; Sihem Benaboud
Journal:  Clin Pharmacokinet       Date:  2017-05       Impact factor: 6.447

9.  Very high concentrations of active intracellular phosphorylated emtricitabine in neonates (ANRS 12109 trial, step 2).

Authors:  Déborah Hirt; Alain Pruvost; Didier K Ekouévi; Saïk Urien; Elise Arrivé; Mamourou Kone; Eric Nerrienet; Mandisa Nyati; Glenda Gray; Leang Sim Kruy; Stéphane Blanche; François Dabis; Jean-Marc Tréluyer
Journal:  Antimicrob Agents Chemother       Date:  2011-04-04       Impact factor: 5.191

10.  Population pharmacokinetics of emtricitabine in HIV-1-infected adult patients.

Authors:  Elodie Valade; Jean-Marc Tréluyer; Naïm Bouazza; Jade Ghosn; Frantz Foissac; Sihem Benaboud; Floris Fauchet; Jean-Paul Viard; Saïk Urien; Déborah Hirt
Journal:  Antimicrob Agents Chemother       Date:  2014-02-03       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.